Amanote Research
Register
Sign In
Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN- -2a With and Without Cytarabine in Patients With Chronic Myelogenous Leukemia
Clinical Cancer Research
- United States
doi 10.1158/1078-0432.ccr-05-0882
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
September 1, 2005
Authors
M. Talpaz
Publisher
American Association for Cancer Research (AACR)
Related search
Lipoatrophy in GH Deficient Patients Treated With a Long-Acting Pegylated GH
European Journal of Endocrinology
Medicine
Endocrinology
Metabolism
Diabetes
P53 in Chronic Myelogenous Leukemia in Acute Phase.
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Dasatinib Induces Severe Hemorrhagic Colitis in a Patient With Accelerated Phase of Chronic Myelogenous Leukemia
Korean Journal of Internal Medicine
Internal Medicine
A Phase I Study of Selinexor in Combination With High-Dose Cytarabine and Mitoxantrone for Remission Induction in Patients With Acute Myeloid Leukemia
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Increased Cortical Bone Mineralization in Imatinib Treated Patients With Chronic Myelogenous Leukemia
Haematologica
Hematology
Chronic Myelogenous Leukemia
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Pharmacoeconomic Analysis of Dasatinib as a Second-Line Therapy in Patients With Chronic Myelogenous Leukemia
Pharmacoeconomics: theory and practice
Medication Adherence, Molecular Monitoring, and Clinical Outcomes in Patients With Chronic Myelogenous Leukemia in a Large HMO
Journal of the American Pharmacists Association : JAPhA
Pharmacology
Pharmacy
Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
